

**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions and listings of claims in the application:

Claims 1-37. (Cancelled)

38. (Previously presented) A compound chosen from 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-[[1-(N-methylcarbamoylmethyl)piperidin-4-yl]-oxy]quinazoline and its pharmaceutically acceptable salts.

39. (Currently amended) ~~The compound according to claim 38, wherein said compound is~~ 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-[[1-(N-methylcarbamoylmethyl)piperidin-4-yl]-oxy]quinazoline.

40. (Currently amended) ~~The compound according to claim 38, wherein said compound is a~~ A pharmaceutically acceptable salt of 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-[[1-(N-methylcarbamoylmethyl)piperidin-4-yl]-oxy]quinazoline.

41. (Previously presented) A pharmaceutical composition comprising at least one compound chosen from 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-[[1-(N-methylcarbamoylmethyl)piperidin-4-yl]-oxy]quinazoline and its pharmaceutically acceptable salts in association with a pharmaceutically-acceptable diluent or carrier.

42. (Currently amended) ~~The pharmaceutical composition according to claim 41, wherein said~~ A pharmaceutical composition ~~comprises~~ comprising 4-(3-chloro-2-

fluoroanilino)-7-methoxy-6-[[1-(N-methylcarbamoylmethyl) piperidin-4-yl]oxy]-  
quinazoline in association with a pharmaceutically-acceptable diluent or carrier.

43. (Currently amended) ~~The pharmaceutical composition according to claim 41,~~  
~~wherein said~~ A pharmaceutical composition ~~comprises~~ comprising a pharmaceutically  
acceptable salt of 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-[[1-(N-  
methylcarbamoylmethyl)piperidin-4-yl]-oxy]quinazoline in association with a  
pharmaceutically-acceptable diluent or carrier.

Claims 44 - 71 (Cancelled)